This is the compilation of articles by late B.Chandrasekhar,a spirited human rights activist, sharp intellectual, impressive speaker and Special Public Prosecutor in the Tsundur massacre case.
Ganz konkret: Sie brauchen ein Konzeptionelles System, Software und die entsprechenden Dienstleister und Outsourcingpartner, das ist alles. Einmal angestoßen, arbeitet Ihr Vertrieb vollautomatisch und Sie haben wieder Zeit, sich auf Ihre eigentlichen Kernaufgaben zu konzentrieren.
PreSales Marketing
Entlastet wertvolle Vertriebsmitarbeiter durch Automatisierung von Routineaufgaben
Sorgt für einen stetigen Zustrom an Interessenten, die sich durch direkte und persönliche Beziehungen zu echten Stammkunden entwickeln
Ist ein System, das sich auf nahezu jede Branche und jedes Unternehmen anwenden lässt
Verursacht geringe Kosten und spart durch effiziente, schlanke Prozesse noch laufende kosten ein!
Nutzen Sie die Gelegenheit, sich hier auf den folgenden Seiten umfassend über PreSales Marketing und die Möglichkeiten der automatisierten Vertriebsanbahnung zu informieren. Verlassen Sie den Kreislauf der lästigen Routinearbeit!
http://www.presalesmarketing.com/
This is the compilation of articles by late B.Chandrasekhar,a spirited human rights activist, sharp intellectual, impressive speaker and Special Public Prosecutor in the Tsundur massacre case.
Ganz konkret: Sie brauchen ein Konzeptionelles System, Software und die entsprechenden Dienstleister und Outsourcingpartner, das ist alles. Einmal angestoßen, arbeitet Ihr Vertrieb vollautomatisch und Sie haben wieder Zeit, sich auf Ihre eigentlichen Kernaufgaben zu konzentrieren.
PreSales Marketing
Entlastet wertvolle Vertriebsmitarbeiter durch Automatisierung von Routineaufgaben
Sorgt für einen stetigen Zustrom an Interessenten, die sich durch direkte und persönliche Beziehungen zu echten Stammkunden entwickeln
Ist ein System, das sich auf nahezu jede Branche und jedes Unternehmen anwenden lässt
Verursacht geringe Kosten und spart durch effiziente, schlanke Prozesse noch laufende kosten ein!
Nutzen Sie die Gelegenheit, sich hier auf den folgenden Seiten umfassend über PreSales Marketing und die Möglichkeiten der automatisierten Vertriebsanbahnung zu informieren. Verlassen Sie den Kreislauf der lästigen Routinearbeit!
http://www.presalesmarketing.com/
Sadece lastik yıkama ekipmanları üreten Çek Cumhuriyeti kuruluşu PEAKWASH, geniş portföyü ile tüm lastik yıkama ihtiyaçlarını karşılar.
Kolay kurulum, dayanıklılık ve yüksek performans,makul satınalma ve bakım maliyetleri; farklı üretim taleplerini karşılamada esneklik PEAKWASH'ın temel özellikleridir.
Der Alltag in den meisten Unternehmen besteht in immer gleichen Abläufen, wiederkehrenden und unbefriedigenden Aufgaben und vor allem der mühsamen Suche nach Neukunden. Die aber lassen sich kaum noch ansprechen über klassische Marketingwege. Das demotiviert Unternehmer und ihre Angestellten, der Vertrieb ist weniger effizient als er sein könnte und belastet mit Routinearbeiten. Wollen Sie zurück zu Ihrem Kerngeschäft, während kaufbereite Interessenten von allein auf Ihre Angebote stoßen? Dann legen Sie entweder Ihren Vertrieb in mitunter teure Dienstleister-Hände oder stellen Ihn selbst auf Autopilot um.
Die Kosten für den Vertrieb auf Autopilot, ja selbst das Unternehmen auf Autopilot sind niedrig, teils sind lediglich Investitionen im unteren einhundert Euro Bereich notwendig. Ganz konkret: Sie brauchen ein Konzeptionelles System, Software und die entsprechenden Dienstleister und Outsourcingpartner, das ist alles. Einmal angestoßen, arbeitet Ihr Vertrieb vollautomatisch und Sie haben wieder Zeit, sich auf Ihre eigentlichen Kernaufgaben zu konzentrieren.
PreSales Marketing
Entlastet wertvolle Vertriebsmitarbeiter durch Automatisierung von Routineaufgaben
Sorgt für einen stetigen Zustrom an Interessenten, die sich durch direkte und persönliche Beziehungen zu echten Stammkunden entwickeln
Ist ein System, das sich auf nahezu jede Branche und jedes Unternehmen anwenden lässt
Verursacht geringe Kosten und spart durch effiziente, schlanke Prozesse noch laufende kosten ein!
Nutzen Sie die Gelegenheit, sich hier auf den folgenden Seiten umfassend über PreSales Marketing und die Möglichkeiten der automatisierten Vertriebsanbahnung zu informieren. Verlassen Sie den Kreislauf der lästigen Routinearbeit!
http://www.presalesmarketing.com/
تا زمان انتشار این گزارش مجموع تعداد نمایش آگهی از ۲۰۰ میلیون گذشته و ۸ میلیون نصب از آن به دست آمده است. رکورد تعداد نمایش آگهی یک برنامه ۲,۴ میلیون بار نمایش بوده است. استفادهکنندگان از ابزار تبلیغات در جستوجوی بازار در این گزارش میتوانند نرخ هزینه متوسط تبلیغات (CPI) در جستوجوی بازار را در دستههای مختلف ببینید. آمارها نشان میدهد نرخ تبدیل شدن به خریدار در بین کاربرانی که برنامه را از طریق تبلیغات در جستوجو نصب میکنند ۴۵٪ بیشتر از کاربرانی است که برنامه را از راه جستوجوی عادی نصب میکنند.
سیستم آموزشی کارآمد و پیشرفته در مدارس کانادا تعداد زیادی از خانوادهها را برای ثبتنام فرزندشان جهت تحصیل در مقطع دبیرستان به عنوان یکی از مهمترین پایههای تحصیلی در مدارس کانادا ترغیب میکند. دبیرستان، دورهای است که دانشآموزان، باید با یک انتخاب درست، مسیر خود را برای آینده شغلی و تحصیلی رقم بزنند. به همین دلیل تحصیل در مدارس با کیفیت کانادا برای بسیاری از اشخاصی که میخواهند در جهت رشد و شکوفایی استعداد خود گام بردارند مرحله حساسی است. برای تعداد زیادی از متقاضیان تحصیل در دبیرستانهای کانادا سوالاتی در رابطه با شرایط تحصیل، هزینهها و سیستم آموزشی حاکم بر این مقطع تحصیلی ایجاد میشود. برای دست یافتن به پاسخ سوالات خود در این مقاله با ما همراه باشید.
https://trustimm.com/study-high-school-in-canada/
گزارش توسعهدهندگان بازار در فصل بهار ۱۳۹۸Bazaar Insight
در گزارش فصلی بهار ۹۸ کافهبازار به موضوعات جدیدی از جمله هزینه تبلیغات در جستوجوی بازار هم پرداخته شده است. همچنین توسعهدهندگان هر استان که پرنصبترین برنامهها را تولید کردهاند به تفکیک استانی معرفی شدهاند که فایل کاملتر آن را در اینجا میتوانید مشاهده کنید. در این گزارش همچنین میتوانید اطلاعات دستگاههای اندرویدی کاربران بازار، ساعت خرید کاربران بازار، تغییرات نصب فعال دستههای مختلف در فصل جدید و تغییرات تعداد برنامههای منتشرشده در هر دسته را مشاهده کنید.
در چرخه حسابداری، روند زیر تشریح میشود:
1- تجزیه و تحلیل فعالیتهای مالی
2- ثبت آثار فعالیتهای مالی
(در دفتر روزنامه)
3- تلخیص آثار فعالیتهای مالی
(انتقال ثبتهای دفتر روزنامه به دفتر کل و تهیه تراز آزمایشی)
4- تهیه گزارشها
(تعدیل حسابها، تهیه صورتهای مالی و بستن حسابها)
د. ماجدة الجارودي - ملتقى سيدات الأعمال الثقافي الثالثRiyadhBWF
ورشة عمل: (القيادة المبدعة ـــ القيادة التحويلية).
د. ماجدة الجارودي
ملتقى سيدات الأعمال الثقافي الثالث فندق الأنتركونتننتال الرياض برعاية الغرفة التجاري القسم النسائي
แนวทางการจัดการความเสี่ยงที่ส่งผลต่อต้นทุนการจัดการสินค้าคงคลัง
ของร้านขายยา CDE ในจังหวัดขอนแก่น
The Approach of Risk Management that Affecting the
Inventory Management Cost of CDE Drugstore in Khonkaen Province
Best Practice in Communication
ราชวิทยาลัยกุมารแพทย์แห่งประเทศไทย สมาคมกุมารแพทย์แห่งประเทศไทย
บรรณาธิการ วินัดดา ปิยะศิลป์ วันดี นิงสานนท์
ISBN 978-616-91972-1-8
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea ...Utai Sukviwatsirikul
Saccharomyces boulardii in the prevention of antibiotic-associated
diarrhoea in children: a randomized double-blind placebo-controlled
trial
M. KOTOWSKA, P. ALBRECHT & H. SZAJEWSKA
Department of Pediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland
Accepted for publication 24 November 2004
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
9. 9§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
References:
1. Locke GR, Zinsmeister AR, Fett SL, Melton LJ, Talley NJ. Overlap of gastrointestinal symp-
tom complexes in a US community. Neurogastroenterol Motil 2002;17:29-34.
2. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the
general population: Overlap and lack of stability over time. Gastroenterology 1995;109:671-680.
3. Whitehead WE, Palsson OS, Levy RR, Feld AD, Turner M, Von Korff M . Comorbidity in
irritable bowel syndrome. Am J Gastroenterol 2007;102:2767-2776.
4. Kennedy TM, Jones RH, Hungin AP, Oûflanagan H, Kelly P. Irritabale Bowel Syndrome,
Gastro-oesophageal reflux, and bronchial responsiveness in the general population. Gut 1998;
43:770-774
5. Frissora CL and Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with
other conditions. Curr Gastroenterol Rep 2005;7:264-271.
23. 22 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
°“√»÷°…“µà“ßÊ ¡’§«“¡À≈“°À≈“¬¢Õß®”π«π·≈–™π‘¥ ¡ÿπ‰æ√∑’Ë„™â·≈–µâÕߧ”π÷ß
∂÷ßæ‘…®“°§«“¡‰¡à∫√‘ ÿ∑∏‘Ï„π ¡ÿπ‰æ√π—ÈπÊ ¥â«¬´÷Ëß∑”„À⇪ìπ¢âÕ®”°—¥¢Õß ¡ÿπ‰æ√
∑’Ë®–π”¡“„™â„À⇰‘¥ª√–‚¬™πå„π°“√√—°…“13
20.5 °“√Ωí߇¢Á¡ ®“°°“√»÷°…“∑’ˇªìπ systematic review æ∫«à“‰¡à “¡“√∂
√ÿª‰¥â«à“°“√Ωí߇¢Á¡‰¥âª√–‚¬™πå„π°“√√—°…“‚√§≈”‰ â·ª√ª√«π ‡π◊ËÕß®“°º≈°“√√—°…“
¡’∑—Èß∑’Ë∑”„ÀâÕ“°“√¥’¢÷Èπ·≈–‰¡à¥’¢÷Èπ ®÷ßµâÕß°“√°“√»÷°…“‡æ‘Ë¡‡µ‘¡Õ’°¡“°°àÕπ∑’Ë®–
·π–π”°“√Ωí߇¢Á¡„À⇪ìπÀπ÷Ëß„π·π«∑“ß°“√√—°…“13
20.6 Biofeedback therapy
Biofeedback therapy28
À√◊Õ°“√Ωñ°‡∫àßÕÿ®®“√– ¡’√“¬ß“π«à“¡’ª√–‚¬™πå„π
ºŸâªÉ«¬≈”‰ â·ª√ª√«π™π‘¥∑âÕߺŸ°‡¥àπ∑’Ë¡’ªí≠À“‡∫à߉¡à∂Ÿ°«‘∏’ (anismus) √à«¡¥â«¬
‚¥¬æ∫«à“∂⓺ŸâªÉ«¬ “¡“√∂Ωñ°‡∫àß®π “¡“√∂‡∫àßÕÿ®®“√–‰¥â∂Ÿ°«‘∏’ Õ“°“√ª«¥·πàπ
∑âÕß®“°≈”‰ â·ª√ª√«π®–¥’¢÷Èπ —¡æ—π∏å°—∫°“√§≈“¬µ—«¢ÕßÀŸ√Ÿ¥∑«“√Àπ—°¢≥–‡∫àß
∑’Ë¥’¢÷Èπ ¥—ßπ—ÈπºŸâªÉ«¬≈”‰ â·ª√ª√«π™π‘¥∑âÕߺŸ°‡¥àπ∑’Ë¡’Õ“°“√√∫°«π¡“°À√◊Õ¥◊ÈÕµàÕ
°“√√—°…“ °“√µ√«®°“√∑”ß“π¢Õß∑«“√Àπ—° ‡™àπ anorectal manometry, balloon
expulsion test À√◊Õ defecogram ‡æ◊ËÕ§âπÀ“¿“«–‡∫à߉¡à∂Ÿ°«‘∏’ (anismus) ·≈–
„Àâ°“√√—°…“‚¥¬«‘∏’ biofeedback ®÷ßπà“®–¡’ª√–‚¬™πåµàÕºŸâªÉ«¬
References :
1. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable
bowel syndrome in North America. Am J Gastroenterol 2002;97 (Suppl 11):S7- 26.
2. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treat-
ments for irritable bowel syndrome: a European perspective. Aliment Pharmacol Ther 2006;24:183
- 205.
3. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features
in irritable bowel syndrome and functional dyspepsia. Gut 2004;53:666-72.
4. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, Vakil NB, Simel DL, Moayyedi P. Will the
history and physical examination help establish that irritable bowel syndrome is causing my
patientûs lower gastrointestinal symptoms? JAMA 2008;300:1793-805.
5. Cash BD, Schemed P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome
patients: a systematic review. Am J Gastroenterol 2002;97:2812-9.
6. American Gastroenterological Association. AGA medical position statement: Irritable bowel
syndrome. Gastroenterology 2002;123:2105-7.
7. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br
Med J 1978;277:653-4.
8. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the
physician-patient interaction. Ann Intern Med 1995;122:107-12.
9. Spiegel BMR, Nalibo7 B, Mayer E, et al. The effectiveness of a model physician-patient
relationship versus usual care in irritable bowel syndrome: a andomized controlled trial. Gastro-
enterology 2006;130:A773.
10. Simren M, Mansson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the
irritable bowel syndrome. Digestion 2001;63:108-15.
24. 23§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
11. Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional
dyspepsia? A systematic review. NeurogastroenterolMotil 2006;18:595-607.
12. Atkinson W, Sheldon T, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in
irritable bowel syndrome: a randomized controlled trial. Gut 2004;53:1459-64.
13. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American College of Gastroenterology Task
Force on Irritable Bowel Syndrome. An evidence-based position statement on the management
of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1-35.
14. Robinson A , Lee V, Kennedy A , et al. A randomized controlled trial of self-help interventions
in patients with a primary care diagnosis of irritable bowel syndrome. Gut 2006;55:643-648.
15. Whitehead WE, Palsson O, Jones KR.. Systematic review of the comorbidity of irritable bowel
syndrome with other disorders: what are the causes and implications? Gastroenterology
2002;122:1140-56.
16. Miller AR, North CS, Clouse RE, Wetzel RD, Spitznagel EL, Alpers DH. The association of
irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001;13:25-30.
17. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable
bowel syndrome: a systematic review and meta-analysis .J Consult Clin Psychol 2004;72:
1100-13.
18. Ford A, Talley N, Schoenfeld P, et al. Efficacy of psychological therapies in irritable bowel
syndrome: systematic and meta-analysis. Am J Gastroenterol 2008;103 (Suppl 1):S477.
19. Webb AN, Kukuruzovic RH, Catto-Smith AG, Sawyer SM. Hypnotherapy for treatment of
irritable bowel syndrome. Cochrane Database Syst Rev 2007 (4) CD005110.
20. Drossman D, Toner B, Whitehead W, et al. Cognitive-behavioral therapy vs. education and
desipramine vs. placebo for moderate to severe functional bowel disorders. Gastroenterology
2003; 125:19-31.
21. Tan G, Hammond D, Gurrala J. Hypnosis and irritable bowel syndrome: a review of efficacy and
mechanism of action. Am J Clin Hypnosis 2005;47:161-178.
22. Whelan K. Probiotics and prebiotics in the management of IBS: a review of recent clinical trials
and systematic reviews. Curr Opin Clin Nutr Care 2011;14:531-7.
23. McFarland LV, Dubin S. Meta-analysis of probiotics for the treatment of IBS. World J Gastroenterol
2008;14:2650-61.
24. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of
IBS; a systematic review. Am J Gastroenterol 2009;104:1033-49.
25. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of IBS: a
systematic review. Gut 2010;59:325-32.
26. Liu J, Yang M, Liu Y, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel
syndrome. Cochrane Database Syst Rev 2006 ;(1):CD004116.
27. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal
preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Ali-
ment Pharmacol Ther 2004;19:271-279.
28. Patcharatrakul T, Gonlachanvit S. Outcome of biofeedback therapy in dyssynergic defecation
patients with and without irritable bowel syndrome. J Clin Gastroenterol 2011; 45(7):593-598.
28. 27§”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
‚√§°√¥‰À≈¬âÕπÀ√◊Õ functional dyspepsia ‡À≈◊ËÕ¡´âÕπ‰¥â„π¢≥–‡¥’¬«°—π ‚¥¬
¡’§«“¡™ÿ°Õ¬Ÿà√“« 11-27 %15
ºŸâªÉ«¬¡—°¡’Õ“°“√¡“°°«à“ºŸâ∑’Ë¡’¿“«–Àπ÷Ëß¿“«–„¥
‡æ’¬ßÕ¬à“߇¥’¬« ®÷ßæ∫‰¥â¡“°„π ∂“π欓∫“≈√–¥—∫µµ‘¬¿Ÿ¡‘ ·≈–¡—°¡’ psychiatric
comorbidity16
Õ—πÕ“®‰¥â√—∫ª√–‚¬™π宓°°“√ª√–‡¡‘π·≈–√—°…“∑“ß®‘µ‡«™ à«πÕ“°“√
¢Õß·µà≈–¿“«–·π–π”„Àâ√—°…“·¬°®“°°—π
Reference
1. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth musclerelaxants in the
treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61.
2. Jackson JL, OûMalley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional
gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;
108:65-72.
3. Lavo B, Stenstam M, Nielsen A-L. Loperamide in treatment of irritable bowel syndrome - A
double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;22:77-80.
4. Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide,
codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980;79:1272-
5.
5. Nicandro JP, Shin P, Chuang E. Evaluation of treatment continuation with alosetron by IBS-D
severity criteria. Curr Med Res Opin 2012;28:449-56.
6. Lee KJ, Kim NY , Kwon JK , et al. Efficacy of ramosetron in the treatment of male patients with
irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with
mebeverine. Neurogastroenterol Motil 2011;23:1098-104.
7. PimentelM, Lembo A, Chey WD, et al. Rifaximin Therapy for Patients with Irritable Bowel
Syndrome without Constipation. New Engl J Med 2011;364:22-32.
8. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet
1994;344:39-40.
9. Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut
1987;28:1510-13.
10. Bijkerk CJ, Muris JWM, Knottnerus JA, Hoes AW, De Wit NJ. Systematic review: the role of
different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther
2004;19:245-51.
11. Attar A, Lemann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electro-
lyte solution with lactulose for treatment of chronic constipation. Gut 1999;44:226-30.
12. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient out-
comes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with
constipation. Aliment Pharmacol Ther 2012;35:587-99.
13. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel
syndrome and chronic constipation. Cochrane Database Syst Rev 2007:CD003960.
14. Wensel TM, Luthin DR. Linaclotide: a novel approach to the treatment of irritable bowel syn-
drome. Ann Pharmacother 2011;45:1535-43.
15. Suzuki H, Hibi T. Overlap syndrome of functional dyspepsia and irritable bowel syndrome - are
both diseases mutually exclusive? J Neurogastroenterol Motil 2011;17:360-5.
29. 28 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
16. Piacentino D, Cantarini R, Alfonsi M, et al. Psychopathological features of irritable bowel
syndrome patients with and without functional dyspepsia: a cross sectional study. BMC
Gastroenterol 2011;11:94.
17. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. çProkinetic-treatment of constipation-
predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol
1991;13:49-57.
18. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3
antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analy-
sis. Am J Gastroenterol 2009;104:1831-43.
19. Nakamura M, Ohmiya N, Miyahara R, et al. Are symptomatic changes in irritable bowel syn-
drome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 recep-
tor agonist mosapride. Hepatogastroenterology 2011;58:453-8.
31. 30 §”·π–𔇰’ˬ«°—∫‚√§≈”‰ â·ª√ª√«π ”À√—∫·æ∑¬å∑—Ë«‰ª (·π«∑“߇«™ªØ‘∫—µ‘) 2012
∑“ß®‘µ‡«™‰¥â¡“°°«à“ª√–™“°√∑—Ë«‰ª¥—ß°≈à“«¡“¢â“ßµâπ ºŸâªÉ«¬ IBS ∑’Ë¡’ªí≠À“
∑“ß®‘µ‡«™§«√‰¥â√—∫°“√¥Ÿ·≈√—°…“√à«¡‰ª¥â«¬°—π∑—Èß Õߪí≠À“
References
1. Lee S, Wu J, Ma YL, Tsang A, Guo WJ, Sung J. Irritable bowel syndrome is strongly associated
with generalized anxiety disorder: a community study. Aliment Pharmacol Ther 2009;30:643-
51.
2. Choung RS, Locke R, Zinsmeistr AR, Schleck CD, Talley NJ. Psychosocial distress and somatic
symptoms in community subjects with irritable bowel syndrome: a psychological component is
the rule. Am J Gastroenterol 2009;104:1772-9.
3. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety,
and depression: a meta-analytic review. Psychosomatic Medicine 2003;65:528-33.
4. Gros DF, Antony MM, McCabe RE, Swinson RP. Frequency and severity of the symptoms of
irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disorders
2009;23:290-6.
5. Creed F, Tomenson B, Guthrie E, et al. The relationship between somatization and outcome in
patients with severe irritable bowel syndrome. J of Psychosomatic Res 2008;64:613-20.
6. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients with irritable bowel
syndrome and comorbid depression. Clin Ther 2010;32:1221-33.
¢âÕ √ÿª∑’Ë 24.
°“√ «π≈â“ß≈”‰ âÕ“®∑”„ÀâÕ“°“√≈”‰ â·ª√ª√«π¥’¢÷Èπ™—Ë«§√“«·µàº≈¥’À√◊Õ
º≈‡ ’¬√–¬–¬“«¬—߉¡à¡’¢âÕ¡Ÿ≈∑“ß°“√·æ∑¬å™—¥‡®π
„πºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√∑âÕߺŸ°‡ªìπª√–®”°“√ «π≈â“ß≈”‰ â
Õ“®∑”„ÀâÕ“°“√¥’¢÷Èπ™—Ë«§√“«·µà‰¡à§«√∑”‡ªìπª√–®”‡π◊ËÕß®“°‰¡à¡’¢âÕ¡Ÿ≈∑“ß°“√
·æ∑¬å∑’Ë∫àß∫Õ°∂÷ߺ≈¥’À√◊Õº≈‡ ’¬√–¬–¬“«
„πºŸâªÉ«¬≈”‰ â·ª√ª√«π∑’Ë¡’Õ“°“√§àÕπ‰ª∑“ß∑âÕ߇ ’¬°“√ «π≈â“ß≈”‰ ≡àπà“
®–‰¥âª√–‚¬™πå„¥ Ê